In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

70Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 μg/ml); the geometric mean MIC (0.26 μg/ml) was significantly lower (23-80-fold) than those of itraconazole, voriconazole, posaconazole, and isavuconazole (all P < .001), and amphotericin B (P < .05). F901318 also had good activity against S. apiospermum, S. aurantiacum, and S. boydii, comparable to that of voriconazole and posaconazole but was more active than isavuconazole for all three species.

Cite

CITATION STYLE

APA

Biswas, C., Law, D., Birch, M., Halliday, C., Sorrell, T. C., Rex, J., … Chen, S. C. A. (2018). In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Medical Mycology, 56(8), 1050–1054. https://doi.org/10.1093/mmy/myx161

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free